HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX)
InflaRx N.V. (NASDAQ:IFRX - Free Report) - Analysts at HC Wainwright issued their Q3 2026 EPS estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller...
MarketBeat·3d ago
More News
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim
Guggenheim cut their target price on InflaRx from $22.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday...
MarketBeat·5d ago
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright
InflaRx N.V. (NASDAQ:IFRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller anticipates that the company will post earnings of ($0.14) per share...
MarketBeat·5d ago
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Misses Expectations By $0.03 EPS
InflaRx (NASDAQ:IFRX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by...
InflaRx (IFRX) delivered earnings and revenue surprises of +2.86% and -117.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
InflaRx (IFRX) to Release Earnings on Thursday
InflaRx (NASDAQ:IFRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·14d ago
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer's 36th Annual Healthcare Life Sciences...
MarketBeat·28d ago
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit...
MarketBeat·1mo ago
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One research...
MarketBeat·2mo ago
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the stock, MarketBeat reports. One...